Pre-Conference Day
Monday, February 26, 2024
Non-Oncology Track
8:30 am Morning Registration & Coffee
9:20 am Chair’s Opening Remarks
Exploring Advancements in Next-Generation Conjugates for Neuromuscular Disorders
9:30 am Discovering the FORCETM Platform: Leveraging Potential to Deliver a Transformative Antibody- Oligonucleotide Conjugate Therapy for DM1 (Myotonic Dystrophy Type 1)
Synopsis
- Uncovering pre-clinical proof-of-concept with the FORCE platform in mouse models of myotonic dystrophy type 1
- Outlining the pharmacology of the FORCE platform in nonhuman primates
- Overcoming challenges of targeted delivery to the central nervous system with the FORCE platform
10:00 am Enabling Extrahepatic siRNA Delivery as Potential Therapeutic Agents in Neuromuscular Disorders
Synopsis
- Discovering how targeted tissue delivery of siRNAs allows a more flexible and tailored approach to RNA delivery
- Exploring novel targeting ligands and strategies for enhanced siRNA delivery
- Leveraging improved CNS delivery of siRNA in neurological diseases
10:30 am Morning Refreshments & Networking Break
Utilizing Innovative Conjugates to Gain Successful Therapeutic Effects Beyond Oncology
11:30 am Roundtable Discussion: Exploring the Mechanism of Immunosuppressive Antagonist Steroids (Glucocorticoid Receptor Modulator) Payloads on Inflammatory Diseases to Open a New Avenue of Therapeutic Options
Synopsis
- Discovering how Glucocorticoid receptor modulator steroids are being developed to treat inflammatory diseases such as Crohn’s and Rheumatoid Arthritis
- Benchmarking safety profiles of steroid payloads against traditional ADC payloads and understanding the major translational challenges in traditional inflammation drug development
- Leveraging steroid payloads to open up a new class of novel conjugates and therapeutic applications of next-generation ADCs
12:00 pm Exploring the Development of AMG 133: Utilizing GLP-1 Agonist Peptides to Tackle Obesity
Synopsis
- Exploring site-specific conjugation of peptides to monoclonal antibodies
- Improving metabolic stability of bispecific conjugates through antibody and peptide engineering
- Identifying clinical candidate for the treatment of obesity using preclinical models
12:30 pm Lunch
Understanding Mechanisms of Action of Novel Conjugates to Develop Successful Non-Oncology Targeted Therapeutics Paired With Optimal Targeting Moiety, Linker and Payload Technology
1:30 pm Introduction to Dyne’s FORCE Platform
Synopsis
- Discovery of our anti-TfR1 delivery vehicle
- Conjugation of diverse oligonucleotide payloads
- Application to Duchenne Muscular Dystrophy (DMD)
2:00 pm Exploring How Conjugates Revolutionized the Therapeutic Potential of Nucleic Acids Medicines
Synopsis
- Exploring the development of lipid conjugates
- Understanding the history and future applications of GalNAc conjugates and lessons from approved medicines
- Leveraging lipid conjugates to overcome hurdles in CNS delivery for neurological indications
2:30 pm Chair’s Closing Remarks
2:40 pm End of Pre-Conference Day
Workshop Track
8:30 am Morning Registration & Coffee
Workshop A
9:00 am WORKSHOP A: Exploring & Optimizing the Pairing of Targeting Moiety & Target Biology
Synopsis
With such a wide variety of next-generation conjugates being developed, a key consideration for the lesser understood formats in novel conjugates is the target selection.
If you are going to make one correct decision during the drug development process, selecting the right target is crucial for clinical success.
By ensuring an improved understanding of different targeting moieties and target biology, you can ensure you are selecting the optimal target for your next-generation conjugate.
This workshop is an ideal opportunity to leverage the knowledge of your peers and participate in deep-dive discussion to help you to hit the ground running in getting the first step of your drug development right.
Here’s what you’ll learn:
- Explaining the thought-processes behind target selection in novel-conjugation development
- Linking target biology to mechanism of action of targeting moiety and linker-payload
- Navigating complexities of the variety of novel formats and influencing foresight for successful development
12:00 pm Lunch
Workshop B
1:00 pm WORKSHOP B: Understanding How to Take a Next- Generation Conjugate Through Lead Candidate Selection & Technical Development
Synopsis
Selecting the right candidate and progressing it is a challenge
for all drugs, specifically next-generation conjugates. This workshop is an opportunity to learn and discuss the important aspects of developability assessment and the interface between research and CMC for successful lead selection, development, and manufacturing of novel format conjugates. The workshop will be of interest to Research and CMC leads new to the conjugate field or with experience developing traditional antibody-drug conjugates. It is the optimum space enabling you to think more holistically about the key aspects of next-generation conjugate lead selection and development and to better understand similarities and differences between traditional and next-generation conjugate development programs.
Join this workshop to learn about:
- Developability assessment study design for novel format conjugate selection
- Analytical approaches in developability assessment
- Program integration for developability assessment at the interface between research and CMC